Ming Hsieh - Fulgent Genetics Chairman of the Board and Presidentident, CEO
| FLGT Stock | USD 18.33 0.46 2.57% |
Chairman
Mr. Ming Hsieh is Chairman of the Board, President, Chief Executive Officer of the Company. Mr. Hsieh is Chairman of our Board of Directors, President and Chief Executive Officer. Prior to founding Fulgent, Mr. Hsieh served as Chief Executive Officer, President and Chairman of the board of directors of Cogent, Inc., or Cogent, a biometric identification services and products company he cofounded in 1990, which was acquired by 3M in 2010. Prior to his tenure at Cogent, Mr. Hsieh founded and served as Vice President of AMAX Technology from 1987 to 1990. Mr. Hsieh currently serves on the board of directors of Fortinet, Inc., a network security company traded on the NASDAQ Global Select Market under the symbol FTNT. Mr. Hsieh received a B.S.E.E. from USC in 1983 and an M.S.E.E. from USC in 1984, as well as honorary doctoral degrees from USC in 2010 and the University of West Virginia in 2011. Mr. Hsieh has served as a trustee at USC since 2007 and at Fudan University in China since 2011. In 2015, Mr. Hsieh was elected to the National Academy of Engineering
| Age | 68 |
| Address | 4399 Santa Anita Avenue, El Monte, CA, United States, 91731 |
| Phone | 626 350 0537 |
| Web | https://www.fulgentgenetics.com |
Ming Hsieh Latest Insider Activity
Tracking and analyzing the buying and selling activities of Ming Hsieh against Fulgent Genetics stock is an integral part of due diligence when investing in Fulgent Genetics. Ming Hsieh insider activity provides valuable insight into whether Fulgent Genetics is net buyers or sellers over its current business cycle. Note, Fulgent Genetics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Fulgent Genetics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Ming Hsieh over six months ago Acquisition by Ming Hsieh of 750000 shares of Fulgent Genetics subject to Rule 16b-3 | ||
Ming Hsieh over six months ago Disposition of 8667 shares by Ming Hsieh of Fulgent Genetics at 24.06 subject to Rule 16b-3 |
Fulgent Genetics Management Efficiency
The company has return on total asset (ROA) of (0.0415) % which means that it has lost $0.0415 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1435) %, meaning that it created substantial loss on money invested by shareholders. Fulgent Genetics' management efficiency ratios could be used to measure how well Fulgent Genetics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.16 in 2024. Return On Capital Employed is likely to drop to -0.07 in 2024. At this time, Fulgent Genetics' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 30.5 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 49.4 M in 2024.Similar Executives
| Found 12 records | CHAIRMAN Age | ||
| Matthew Rabinowitz | Natera Inc | 51 | |
| Christopher OConnell | Waters | 51 | |
| James Foster | Charles River Laboratories | 70 | |
| Thomas Lynch | Thermo Fisher Scientific | 66 | |
| Kevin JD | EXACT Sciences | 58 | |
| Robert Spoerry | Mettler Toledo International | 65 | |
| Jim Manzi | Thermo Fisher Scientific | 68 | |
| Steven Rales | Danaher | 73 | |
| Mitchell Rales | Danaher | 67 | |
| Flemming Ornskov | Waters | 62 | |
| Kevin Conroy | EXACT Sciences | 58 | |
| Boon Koh | Agilent Technologies | 70 | |
Management Performance
| Return On Equity | -0.14 | ||||
| Return On Asset | -0.0415 |
Fulgent Genetics Leadership Team
Elected by the shareholders, the Fulgent Genetics' board of directors comprises two types of representatives: Fulgent Genetics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Fulgent. The board's role is to monitor Fulgent Genetics' management team and ensure that shareholders' interests are well served. Fulgent Genetics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Fulgent Genetics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Doreen Ng, VP Office | ||
| DABMG FACMG, Chief Director | ||
| Paul Kim, Chief Officer | ||
| Ming Hsieh, Chairman of the Board and Presidentident, CEO | ||
| Natalie Prescott, General Officer | ||
| Lawrence MD, Chief Officer | ||
| Ray Yin, President Pharma | ||
| Brandon Perthuis, Chief Officer | ||
| Jian Xie, COO President | ||
| Ellen Tsui, Vice Resources | ||
| Jakub Sram, Vice Sales | ||
| Paul CPA, Chief Officer |
Fulgent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Fulgent Genetics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.14 | ||||
| Return On Asset | -0.0415 | ||||
| Profit Margin | (0.59) % | ||||
| Operating Margin | (0.24) % | ||||
| Current Valuation | 342.57 M | ||||
| Shares Outstanding | 30.59 M | ||||
| Shares Owned By Insiders | 32.33 % | ||||
| Shares Owned By Institutions | 54.28 % | ||||
| Number Of Shares Shorted | 645.62 K | ||||
| Price To Earning | 3.95 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Fulgent Stock Analysis
When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.